Tuesday, May 14, 2002

Genentech Appoints Hal Barron Vice President, Medical Affairs

South San Francisco, Calif. -- May 14, 2002 --

Genentech, Inc. (NYSE: DNA) today announced the promotion of Hal Barron, M.D., FACC, to vice president, Medical Affairs.  Barron reports to Susan D. Hellmann, M.D., M.P.H., executive vice president, Development and Product Operations, and chief medical officer.

In his position, Barron is responsible for all Genentech clinical activities including conducting and reporting Phase I-IV clinical trials, drug safety and pharmacovigilance; managing outcomes research and epidemiology; and overseeing product support activities such as medical communications and drug registries.

"Hal’s extensive experience, scientific expertise, strong leadership and knowledge of Genentech make him extremely well-suited to lead Medical Affairs’ vital work," said Hellmann.

Barron, 39, joined Genentech in 1996 as a clinical scientist.  Since that time, he has held positions as associate director and director of Cardiovascular Research.  In 2001, he was named senior director of Specialty BioTherapeutics.

Barron’s academic positions at the University of California, San Francisco (UCSF) include assistant adjunct professor of Epidemiology and Biostatistics and assistant clinical professor of Medicine/Cardiology.

Barron holds a bachelor’s degree in physics from the Washington University School of Engineering and received his doctorate of medicine from the Yale University School of Medicine. He is Board certified in internal medicine and cardiology, and completed his residency at UCSF.

Barron is a member of the editorial boards of the Journal of the American College of Cardiology and Preventative Cardiology and is an ad hoc reviewer for several other cardiology journals.  He has published more than 50 papers in peer-reviewed scientific journals.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs.  Fifteen of the currently approved biotechnology products stem from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA.

 

###